Brief: Urogen Announces Updated 18-Month Duration Of Response (Dor) Of 80.6% From The Phase 3 Envision Trial Of Ugn-102
26/04/2025 23:31
April 26 (Reuters) - Urogen Pharma Ltd UR8.F: UROGEN ANNOUNCES UPDATED 18-MONTH DURATION OF RESPONSE (DOR) OF 80.6% FROM THE PHASE 3 ENVISION TRIAL OF UGN-102, AN INVESTIGATIONAL TREATMENT FOR RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (LG-IR-NMIBC) UROGEN PHARMA LTD - SUBMITS NDA TO FDA FOR UGN-102 Source text: ID:nBw2Mxxjma Further company coverage: UR8.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors